Oesophageal Chemoradiotherapy in the UK--current practice and future directions.

Oesophageal Chemoradiotherapy in the UK--current practice and future directions.

Show other versions (1)

The SCOPE 1 trial closed to recruitment in early 2012 and has demonstrably improved the quality of UK radiotherapy. It has also shown that there is an enthusiastic upper gastrointestinal clinical oncology community that can successfully complete trials and deliver high-quality radiotherapy. Followin...

Full description

Bibliographic Details
Main Authors:	Gwynne, S, Falk, S, Gollins, S, Wills, L, Bateman, A, Cummins, S, Grabsch, H, Hawkins, M, Maggs, R, Mukherjee, S, Radhakrishna, G, Roy, R, Sharma, R, Spezi, E, Crosby, T
Format:	Journal article
Language:	English
Published:	2013

Similar Items

Oesophageal Chemoradiotherapy in the UK-Current Practice and Future Directions
by: Gwynne, S, et al.
Published: (2013)

NeoSCOPE RTTQA: pre-accrual and on-trial review of all patients in a UK oesophageal RT trial
by: Evans, E, et al.
Published: (2018)

Driving developments in UK oesophageal radiotherapy through the SCOPE trials
by: S. Gwynne, et al.
Published: (2019-02-01)

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma
by: Mukherjee, S, et al.
Published: (2017)

NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.
by: Mukherjee, S, et al.
Published: (2015)

NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.
by: Mukherjee, S, et al.
Published: (2015)

4DCT oesophageal tumour delineation in SCOPE2 – how is radiotherapy quality assurance beneficial?
by: Cox, S, et al.
Published: (2018)

Use of a non-endoscopic immunocytological device (Cytosponge™) for post chemoradiotherapy surveillance in patients with oesophageal cancer in the UK (CYTOFLOC): A multicentre feasibility study
by: Christopher M. Jones, et al.
Published: (2022-11-01)

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
by: Crosby, T, et al.
Published: (2013)

Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trialResearch in context
by: Somnath Mukherjee, et al.
Published: (2023-07-01)

Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/− cetuximab in oesophageal cancer
by: Crosby, T, et al.
Published: (2017)

The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: A radiobiological investigation
by: Carrington, R, et al.
Published: (2015)

Can protons reduce bone marrow toxicity in definitive chemoradiotherapy for oesophageal tumours?
by: Warren, S, et al.
Published: (2016)

The influence of dose distribution on treatment outcome in the SCOPE 1 oesophageal cancer trial
by: Carrington, E, et al.
Published: (2016)

Effect of anaemia prevention on survival and local control in oesophageal cancers treated with chemoradiotherapy.
by: Tuan, J, et al.
Published: (2012)

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
by: Mukherjee, S, et al.
Published: (2013)

Discovery of stable and prognostic CT-based radiomic features independent of contrast administration and dimensionality in oesophageal cancer.
by: Concetta Piazzese, et al.
Published: (2019-01-01)

A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network.
by: Adams, R, et al.
Published: (2007)

Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies
by: Leonie K. deKlerk, et al.
Published: (2021-04-01)

Survival after curative chemoradiotherapy or neoadjuvant therapy and surgery converges in higher-risk patients with oesophageal cancer
by: Rana, M, et al.
Published: (2021)

Prediction of pathological response to neo‐adjuvant chemoradiotherapy for oesophageal cancer using vibrational spectroscopy
by: Thi N. Q. Nguyen, et al.
Published: (2021-03-01)

Development and validation of a prognostic model incorporating texture analysis derived from standardised segmentation of PET in patients with oesophageal cancer
by: Foley, KG, et al.
Published: (2017)

Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer
by: Han Gyul Yoon, et al.
Published: (2021-10-01)

Oesophageal and gastro-oesophageal junction tumours
by: Bird-Lieberman, E, et al.
Published: (2007)

Small cell oesophageal carcinoma: an institutional experience and review of the literature.
by: Hudson, E, et al.
Published: (2007)

The effectiveness of neoadjuvant chemoradiotherapy in oesophageal adenocarcinoma with presence of extracellular mucin, signet‐ring cells, and/or poorly cohesive cells
by: Maria J Valkema, et al.
Published: (2023-07-01)

Current and Future Immunotherapy-Based Treatments for Oesophageal Cancers
by: Natalie To, et al.
Published: (2022-06-01)

An analysis of plan robustness for oesophageal tumours: comparing volumetric modulated arctherapy plans and spot scanning proton planning
by: Warren, S, et al.
Published: (2016)

Impact of Percutaneous Endoscopic Gastrostomy Tube Feeding on Nutritional Status in Patients Undergoing Chemoradiotherapy for Oesophageal Cancer
by: Joana Lemos Garcia, et al.
Published: (2022-08-01)

Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma
by: Hyehyun Jeong, et al.
Published: (2021-03-01)

MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma.
by: Becky A S Bibby, et al.
Published: (2015-01-01)

The future of combination immunotherapy in oesophageal adenocarcinoma
by: Maria Davern, et al.
Published: (2023-07-01)

Correction: MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma.
by: PLOS ONE Staff
Published: (2015-01-01)

The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy
by: Jin Zhou, et al.
Published: (2022-11-01)

Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy
by: Chengbing Zeng, et al.
Published: (2021-01-01)

MMS22L Expression as a Predictive Biomarker for the Efficacy of Neoadjuvant Chemoradiotherapy in Oesophageal Squamous Cell Carcinoma
by: Qiyu Luo, et al.
Published: (2021-09-01)

Normal tissue sparing with respiratory adapted volumetric modulated arc therapy for distal oesophageal and gastro-oesophageal tumours.
by: Hafeez, S, et al.
Published: (2014)

Definitive chemoradiation in patients with inoperable oesophageal carcinoma.
by: Crosby, T, et al.
Published: (2004)

Dosimetric parameters predict toxicity in chemoradiotherapy with nelfinavir for pancreatic cancer
by: Holyoake, D, et al.
Published: (2016)

Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients Treated with Definitive Chemoradiotherapy for Locally Advanced Oesophageal Squamous Cell Carcinoma
by: Zhang G, et al.
Published: (2023-01-01)